- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - February 2002
National Cancer Institute®
Last Modified: February 1, 2002
Table of Contents
1
UI - 11464978
AU - Khoury H; Adkins D; Brown R; Pence H; Vij R; Goodnough LT; Westervelt P;
TI -
Trinkaus K; Lin HS; DiPersio Y
Low incidence of transplantation-related acute complications in patients
with chronic myeloid leukemia undergoing allogeneic stem cell
transplantation with a low-dose (550 cGy) total body irradiation
conditioning regimen.
SO - Biol Blood Marrow Transplant 2001;7(6):352-8
AD - Division of Medical Oncology, Bone Marrow Transplantation and Leukemia
Section, Washington University School of Medicine, St. Louis, Missouri
63110-1093, USA. hkhoury@imgate.wustl.edu
Although allogeneic transplantation is a curative therapy for chronic
myeloid leukemia (CML), treatment-related mortality is still a major
cause of posttransplantation mortality, especially for patients older
than 40 years. We investigated, in a phase II trial, the role of a
low-dose (550 cGy) high-dose rate (35 cGy/min) single-exposure total
body irradiation (TBI) conditioning regimen for allogeneic peripheral
blood stem cell (PBSC) transplantation in patients with CML. Between
cytokine-mobilized allogeneic PBSC transplantation from HLA-matched
siblings following administration of cyclophosphamide (60 mg/kg per day
intravenously on days -2 and -1) and single-dose TBI (550 cGy delivered
at 30 cGy/min on day 0). Cyclosporine A alone was administered for
prophylaxis against graft-versus-host disease (GVHD). Median patient age
was 47 years (range, 21-63 years), with 23 patients (77%) older than 40
years. The preparative regimen was well tolerated. Grade 4 toxicities
and oral mucositis were not observed. Graft failure did not occur.
Severe acute GVHD was observed in 5 patients (17%). The median follow-up
was 23 months (range, 6-39 months). Cytogenetic or hematologic relapse
was detected in 3 patients (10%), 2 of whom subsequently entered
remission following a taper of immunosuppression. Nonrelapse mortality
occurred in 5 patients (17%), and the Kaplan-Meier estimate of survival
at 2 years was 83% (95% confidence interval, 70%-97%). In summary, this
low-dose TBI-based preparative regimen resulted in uniform donor
engraftment, with markedly reduced organ toxicity and nonrelapse
mortality, in this relatively older cohort of patients with CML.
2
UI - 11775253
AU - Liu Y; Kleine HD; Engel H; Andreeff M
TI -
Cytokine expression of T cells in chronic myeloid leukemia.
SO - Chin Med J (Engl) 2000 Mar;113(3):232-5
AD - Institute of Hematology, People's Hospital, Beijing Medical University,
Beijing 100034, China.
OBJECTIVE: To evaluate the function of T cells in chronic myeloid
leukemia (CML). METHODS: Interleukin-1 beta (IL-1 beta), interleukin-2
(IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6
(IL-6), tumor necrosis factor alpha (TNF alpha), and granulocyte
macrophage-colony stimulating factor (GM-CSF) gene expressions were
investigated by reverse transcription polymerase chain reaction (RT-PCR)
assay in fluorescence active cell sorter (FACS) sorted peripheral blood
CD2+/CD56-T cells from 12 CML patients, 10 meylodysplastic syndrome
(MDS) patients and 7 normal individuals. RESULTS: TNF alpha mRNA was
transcribed in T cells from all of the CML, MDS and normal individuals.
IL-1 beta mRNA was transcribed in T cells from 10 CML, 9 MDS and 6
normal individuals. Low levels of IL-2 and IL-4 mRNA were detected in 5
CML patients. IL-3, IL-6 and GM-CSF mRNA were undetectable in all
samples. CONCLUSION: IL-4 and IL-2 were expressed abnormally in T cells
of CML.
3
UI - 11793598
AU - Schleuning M; Hiddemann W
TI -
[New molecular therapy options in hematology and oncology, exemplified
by STI571]
SO - Internist (Berl) 2001 Dec;42(12):1591-7
AD - Medizinische Klinik III, Klinikum Grosshadern der
Ludwig-Maximilians-Universitat Munchen.
4
UI - 11792988
AU - Wickenhauser C; Thiele J; Perez F; Varus E; Stoffel MS; Kvasnicka HM;
TI -
Beelen DW; Schaefer UW
Mixed chimerism of the resident macrophage population after allogeneic
bone marrow transplantation for chronic myeloid leukemia.
SO - Transplantation 2002 Jan 15;73(1):104-11
AD - Institute of Pathology, University of Cologne, Joseph-Stelzmannstr. 9,
D-50924 Cologne, Germany.
BACKGROUND: Bone marrow macrophages have been recognized to play a
crucial role in the functional network that constitutes the
microenvironment. In chronic myelogenous leukemia (CML), neoplastic
macrophages are presumably responsible for the expansion of the leukemic
cell clone. So far, no information is available about a persistence of
host-type macrophages after allogeneic bone marrow transplantation (BMT)
implicating a lineage-specific mixed chimerism. METHODS: Bone marrow
trephine biopsies were investigated in eight male and five female
patients with CML after BMT after a sex-mismatched host/donor
constellation. Techniques included immunophenotyping (CD68) for
identification of resident macrophages and a simultaneous genotyping
with X- and Y-chromosome-specific DNA-probes (fluorescence in situ
hybridization). Normal bone marrow and specimens of CML patients before
BMT served as controls. RESULTS: Contrasting an almost 100% congruence
with the genotyping in the controls, a mixed chimerism of the CD68+
macrophages and the other host myeloid cells was found. Until 3 months
after BMT, incidence of host-type macrophages ranged from 8% to 10%.
This feature was also identifiable in the peculiar subset of
pseudo-Gaucher cells (PGCs). The number of host-type macrophages failed
to decline significantly during the early posttransplant period, because
after almost 4 months these were still detectable. On the other hand, in
patients showing an initial-to-manifest leukemic relapse, an insidious
conversion of up to 50% from the donor to host-type macrophages and
myeloid cells occurred. CONCLUSIONS: The CD68+ resident bone marrow
macrophage population including PGCs are involved in the
lineage-specific chimerism and minimal residual disease after BMT in
CML.
5
UI - 11697640
AU - Thiele J; Kvasnicka HM
TI -
Comparative effects of interferon and hydroxyurea on bone marrow
fibrosis in chronic myelogenous leukemia.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):855-62
AD - Institute of Pathology, University of Cologne, Germany.
j.thiele@uni-koeln.de
Therapy-related changes of the bone marrow fiber content remain a
controversial issue in hematopathology. This conflict of opinion firstly
depends on difficulties to determine the quantity of fibers exactly
(semiquantitative grading, morphometry, reference to cellularity).
Secondly, the appropriate selection of patients with specific
monotherapies including hydroxyurea (HU) and interferon-alpha (IFN)
seems to present some problems. Finally, assessment of myelofibrosis is
further biased by the different endpoints of sequential examinations.
The latter shortcoming can be improved upon by the calculation of the
myelofibrosis progression/regression index which describes the ratio
between difference of fiber density and observation time. Using strictly
defined therapeutic regimens and intervals between sequential trephine
biopsies a stimulating effect of IFN administration on bone marrow
fibrosis in Ph1+-chronic myelogenous leukemia (CML) has been found. This
result is comparable with the failure of this agent to improve
myelofibrosis (and splenomegaly) in a considerable number of patients
with allied subtypes of chronic myeloproliferative disorders. This is in
contrast to the effect HU exerts which is a more fibrolytic or even
stabilizing influence on bone marrow fibrosis. This phenomenon is
readily demonstrable by the assessment of dynamic features
(myelofibrosis progression index). In addition, patients showing a rapid
progression of myelofibrosis during IFN and HU treatment of Ph1+-CML are
generally associated with a poor risk outcome and a significant
worsening of survival.
6
UI - 11697642
AU - Clark RE; Christmas SE
TI -
BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid
leukaemia.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):871-80
AD - Department of Haematology, University of Liverpool, United Kingdom.
clarkre@liverpool.ac.uk
The BCR-ABL gene that arises in chronic myeloid leukaemia (CML) is a
neoantigen. Peptides derived from the BCR-ABL fusion junction may
therefore be immunogenic, if appropriately presented to the immune
system. This article reviews data demonstrating that certain junctional
peptides will bind to HLA molecules, and that these peptides will elicit
specific T-lymphocyte responses in vitro, in both normal subjects and in
CML patients. The clinical relevance of these observations is discussed.
7
UI - 11697648
AU - Kitzis A; Brizard F; Dascalescu C; Chomel JC; Guilhot F; Brizard A
TI -
Persistence of transcriptionally silent BCR-ABL rearrangements in
chronic myeloid leukemia patients in sustained complete cytogenetic
remission.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):933-44
AD - Laboratoire de Genetique Cellulaire et Moleculaire, UPRES EA 2622, CHU
de Poitiers, France. a.kitzis@chu-poitiers.fr
Persistence of BCR-ABL rearrangements was demonstrated by D-FISH
technique in chronic myeloid leukemia (CML) patients in complete
cytogenetic response (CCR) after allogeneic bone marrow transplantation
(BMT) or interferon-alpha therapy (IFN-alpha). Samples from bone marrow
aspirate or peripheral blood or both were analyzed by conventional
cytogenetics, Southern blot, fluorescent interphase in situ
hybridization (FISH), and quantitative reverse transcription polymerase
chain reaction (Q-RT-PCR). In all patients, FISH detected 1% to 12%
nuclei with a BCR-ABL fusion gene, whereas Q-RT-PCR were negative or
weakly positive. Based on these results, we hypothesize that the BCR-ABL
genomic rearrangement remains unexpressed in a small percentage of cells
whatever the treatment (IFN-alpha or BMT), and this in spite of the
negativity of the RT-PCR-based classical molecular remission criterion.
These data corroborate those obtained by other investigators and point
to the need for follow-up of CML patients in CCR over an extensive
period, at the DNA level to evaluate the residual disease and at the RNA
level (Q-RT-PCR) to estimate the risk of relapse and guide the
therapeutic decision. Experimental models suggesting the persistence of
positive BCR-ABL cells are discussed and tentative explanations of tumor
"dormancy" are proposed.
8
UI - 11697649
AU - Vey N; Balatzentko G; Lafage M; Sainty D; Bouabdallah R; Chabannon C;
TI -
Blaise D; Gastaut JA; Gabert J
Survey of early disapearance of BCR/ABL fusion transcript after
allogeneic or autologous stem cell transplantation for chronic
myelogenous leukemia.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):945-52
AD - Department of Hematology, Institut Paoli-Calmettes and Universite de la
Mediterranee, Marseille, France. veyn@marseille.fnclcc.fr
The detection of BCR-ABL specific RNA by RT-PCR has been shown to
predict relapse when positive 6 months after allogeneic stem cell
transplantation (SCT) for chronic myelogenous leukemia (CML). In the
present study, the focus was on evaluation of residual disease during
the first weeks following SCT. In this study, 177 blood or marrow
samples were obtained from 33 patients who received allogeneic (20
patients) or autologous (13 patients) SCT on day 0, day 30 and every 3
months for 1 year. T-cell depletion (TCD) was performed in 4 cases. On
day 0 (day of graft infusion), 10/30 evaluable patients had negative
RT-PCR (33%) regardless of pretransplant characteristics. On day 30,
14/18 patients (77%) from the allogeneic group had negative RT-PCR
versus 0% in the autologous group. 2/4 patients who received TCD
allogeneic grafts had day 30-positive PCR. Five patients in the
allogeneic group had at least one positive RT-PCR sample between day 30
and day 90: 3 of them subsequently relapsed suggesting possible
correlation between early positivity and relapse. Our results show that
disappearance of MRD can be achieved within 3 months after
transplantation in the majority of patients treated with allogeneic but
not after autologous SCT. This suggests that the GVL effect might be
operational early during the first weeks following transplantation.
9
UI - 10905245
AU - Gunsilius E; Duba HC; Petzer AL; Kahler CM; Grunewald K; Stockhammer G;
TI -
Gabl C; Dirnhofer S; Clausen J; Gastl G
Evidence from a leukaemia model for maintenance of vascular endothelium
by bone-marrow-derived endothelial cells.
SO - Lancet 2000 May 13;355(9216):1688-91
AD - Division of Haematology and Oncology, University of Innsbruck, Austria.
eberhard.gunsilius@uibk.ac.at
BACKGROUND: Vascular endothelial cells lost from the blood-vessel
endothelium through necrosis or apoptosis must be replaced. We
investigated in a leukaemia model whether bone-marrow-derived
endothelial cells contribute to this maintenance angiogenesis. METHODS:
We studied six patients with chronic myelogenous leukaemia (CML)
carrying the BCR/ABL fusion gene in their bone-marrow-derived cells. We
screened endothelial cells generated in vitro from bone-marrow-derived
progenitor cells and vascular endothelium in myocardial tissue for the
BCR/ABL fusion gene by in-situ hybridisation. For detection of
donor-type endothelial cells after transplantation of haemopoietic stem
cells, recipient tissue was stained with monoclonal antibodies against
donor-type HLA antigens. FINDINGS: We identified the BCR/ABL fusion gene
in variable proportions (0-56%) of endothelial cells generated in vitro.
Endothelial cells expressing the fusion gene were found in the vascular
endothelium of a patient. In a recipient of an allogeneic stem-cell
transplant, normal donor-type endothelial cells were detected in the
vascular endothelium. INTERPRETATION: These findings suggest that CML is
not solely a haematological disease but originates from a
bone-marrow-derived haemangioblastic precursor cell that can give rise
to both blood cells and endothelial cells. Moreover, normal
bone-marrow-derived endothelial cells can contribute to the maintenance
of the blood vascular endothelium. The integration of
bone-marrow-derived endothelial cells into the vascular endothelium
provides a rationale for developing vascular targeting strategies in
vasculopathies, inflammatory diseases, and cancer.
10
UI - 11041417
AU - Garland JM; Kumar S; Heagerty A
TI -
Angiogenesis in chronic myelogenous leukaemia.
SO - Lancet 2000 Sep 16;356(9234):1026-7
11
UI - 11734309
AU - Kearney P; Suter M; Biggs JC
TI -
Rapid clonal development in a relapsed CML 11 years post replete
allogeneic bone marrow transplantation.
SO - Leuk Res 2002 Jan;26(1):111-5
AD - Haematology Department, St Vincent's Hospital Darlinghurst,
Darlinghurst, NSW 2010, Sydney, Australia.
phil.kearney@activebiotech.com
Long-term survival of chronic myeloid leukaemia (CML) patients
transplanted in chronic phase with a replete marrow have been described
previously. The same success has not been achieved with patients in more
advanced stages of the disease. We describe a CML patient who received
an allogeneic bone marrow transplantation in accelerated phase.
Cytogenetic and molecular analysis confirmed donor chimaerism, and the
absence of the BCR-ABL mRNA. Almost 12 years post-transplant relapse was
noted. Cytogenetic analyses showed a complex evolving karyotype. These
findings are correlated with the longitudinal molecular analysis
utilising real-time and VNTR PCR.
12
UI - 11734299
AU - Kishino K; Muroi K; Kawano C; Obata T; Sugano N; Nakagi Y; Nagashima T;
TI -
Watari K; Iwamoto S; Ozawa K
Evaluation of engraftment by ABO genotypic analysis of erythroid
burst-forming units after bone marrow transplantation.
SO - Leuk Res 2002 Jan;26(1):13-7
AD - Division of Cell Transplantation and Transfusion, Jichi Medical School,
Minamikawachi, 329-0498, Tochigi, Japan.
Six patients received an allogeneic bone marrow transplant from
HLA-identical ABO-mismatched donors. ABO genotype of erythroid
burst-forming units (BFU-E) from peripheral blood was analyzed using
polymerase chain reaction with sequence specific primers (PCR-SSP).
After bone marrow transplantation (BMT), engraftment of donor cells by
ABO genotypic analysis of BFU-E was compared with ABO phenotypic
analysis of red blood cells (RBCs). During the early stage after BMT,
ABO genotype of BFU-E in the recipients converted to that of the donors.
In contrast, mixed ABO phenotype of RBCs persisted for about 3 months.
In one patient, autologous hemopoietic cell recovery was detected by the
ABO genotypic analysis before clinical manifestation. ABO genotypic
analysis of BFU-E is relevant for enagraftment after ABO-mismatched BMT.
13
UI - 11734305
AU - Balasubramanian N; Advani SH; Zingde SM
TI -
Protein kinase C isoforms in normal and leukemic neutrophils: altered
levels in leukemic neutrophils and changes during myeloid maturation in
chronic myeloid leukemia.
SO - Leuk Res 2002 Jan;26(1):67-81
AD - Biochemistry and Molecular Biology Division, Cancer Research Institute,
Parel, 400012, Mumbai, India.
Protein kinase C (PKC) is reported to play a role in maturation of the
myeloid cell and functions of the mature neutrophil. The neutrophils in
chronic myeloid leukemia (CML) exhibit defects in several functions. As
a step towards understanding the role of PKC in the defects in function
of the leukemic cells, this study investigates the expression of PKC
isoforms, their subcellular distribution, levels and kinase activity in
the normal and leukemic neutrophils. It also investigates changes in
representative PKC isoforms during myeloid maturation. This study
confirms the presence of PKC alpha, beta and delta and shows, for the
first time, the presence of non conventional PKC isoform theta, atypical
PKC isoform lambda/iota and PKC isoform mu in normal human neutrophils.
In unstimulated cells all the detected PKC isoforms showed a
predominantly cytosolic localisation in normal and CML neutrophils.
Cytosol-membrane distribution of PKC alpha and delta were significantly
altered in leukemic neutrophils as compared to normal cells. Cytosolic
levels of all PKC isoforms were reduced in CML neutrophils with PKC
alpha, beta, iota, theta, and mu showing a significant decrease.
Cytosolic levels of PKC delta contrary to the trend observed for other
PKC isoforms showed a slight increase in CML cells, while its membrane
levels were significantly reduced in CML neutrophils. Total PKC kinase
activity in CML neutrophil cytosol was significantly reduced, while
specific kinase activity of two representative isoforms, PKC alpha and
delta, from normal and CML neutrophils were similar, thereby increasing
the significance of the altered levels of PKC isoforms in CML, and
highlighting their role in the defects in function exhibited by the
leukemic neutrophils. The levels of PKC delta and iota increased and
decreased respectively as the leukemic myeloid cell matured from the
blast to the neutrophil, while the levels of PKC alpha and beta were not
altered. This suggests a role for PKC delta and iota in the maturation
of the leukemic myeloid cell.
14
UI - 11426572
AU - Carella AM
TI -
Mini-ice protocol is better than high-dose hydroxyurea to mobilize
Ph-negative cells in earlier phases of chronic myelogenous leukemia.
SO - Leuk Lymphoma 2001 Jan;40(3-4):447-8
15
UI - 11780326
AU - Fan E; Hu Y; Zhao C
TI -
Human stem cell model to study signal transduction and molecular
regulation mechanisms in CML.
SO - Chin Med J (Engl) 2001 Jul;114(7):680-4
AD - State Key Lab of Experimental Hematology, Institute of Hematology,
Chinese Academy of Medical Science, Tianjin 300020, China.
OBJECTIVE: To develop a primary human hematopoietic stem/progenitor cell
model for chronic myeloid leukemia (CML) and study signal transduction
and molecular regulation mechanisms in CML. METHODS: We developed a
human model of p210BCR/ABL positive CML by transducing normal human
umbilical cord blood CD34+ cells with a retroviral vector containing the
b3a2 bcr/abl cDNA. We also examined whether this model recreated the
cellular phenotype of CML by assessing cell adhesion, cell migration,
cell proliferation and cell survival. RESULTS: We found that
significantly more myeloid colony forming units grew from p210BCR/ABL
expressing cells, adhesion of p210BCR/ABL expressing CD34+ cells to
fibronectin was decreased but migration over fibronectin was enhanced
compared with mock transduced CD34+ cells. In this model, we showed that
the presence of p210BCR/ABL leads to elevated levels of p27kip in
p210BCR/ABL expressing CD34+ cells. We also showed that multidrug
resistance-1 (MDR-1) Pgp was upregulated in the p210BCR/ABL expressing
cells which correlates with the expression of p210BCR/ABL. CONCLUSION:
This primary human CML model recreates most of the features of CML and
provides a useful tool to study signal transduction and downstream
molecular regulation drived by the p210BCR/ABL oncogene in normal CD34+
cells.
16
UI - 11835339
AU - Nakamura Y; Nakazato H; Sato Y; Furusawa S; Mitani K
TI -
Expression of the TEL/EVI1 fusion transcript in a patient with chronic
myelogenous leukemia with t(3;12)(q26;p13).
SO - Am J Hematol 2002 Jan;69(1):80-2
AD - Department of Hematology, Dokkyo University School of Medicine, Tochigi,
Japan.
The t(3;12)(q26;p13) translocation is a recurrent chromosomal aberration
observed in myeloid malignancies. It has been shown that the
translocation results in the fusion of the TEL (ETV6) gene at 12p13 and
the EV11 gene at 3q26. We report the first case with Philadelphia
(Ph)-positive chronic myelogenous leukemia (CML) expressing the TEL/EVI1
fusion transcript. A 26-year-old man was initially diagnosed as having
the chronic phase of Ph-positive CML. The t(3;12)(q26;p13) emerged 16
months prior to the myeloid blastic crisis. Reverse
transcriptase-polymerase chain reaction detected the TEL/EVI1 transcript
without the intervening 5' non-coding exon of EVI1, suggesting that
inappropriate expression of the EVI1 protein driven by the TEL promotor
could play a critical role in progression to the blast crisis of CML.
Copyright 2002 Wiley-Liss, Inc.
17
UI - 11835347
AU - Mubarak AA; Kakil IR; Awidi A; Al-Homsi U; Fawzi Z; Kelta M; Al-Hassan A
TI -
Normal outcome of pregnancy in chronic myeloid leukemia treated with
interferon-alpha in 1st trimester: report of 3 cases and review of the
literature.
SO - Am J Hematol 2002 Feb;69(2):115-8
AD - Hamad Medical Corporation, Department of Medicine, Hematology/Oncology
Division, Doha, Qatar.
Three patients with chronic myeloid leukemia (CML) in chronic phase
received interferon-alpha during pregnancy, starting from the 1st
trimester. No maternal complications were reported. The 3 patients
delivered normal looking babies apart from one baby who was found to
have transient mild thrombocytopenia. Subsequently these children were
followed for 30, 12, and 4 months and all had normal growth and
development. Copyright 2002 Wiley-Liss, Inc.
18
UI - 11683295
AU - Pont V; Miquel FJ; Grau TC; Hernandez F; Sanchez-Carazo JL; Aliaga A
TI -
Skin involvement in chronic myelomonocytic leukaemia as a predictor of
transformation into acute myeloid leukaemia.
SO - J Eur Acad Dermatol Venereol 2001 May;15(3):260-2
AD - Department of Dermatology, Hospital General Universitario, Valencia,
Spain.
We report on the case of a patient with myelodysplastic syndrome (MDS)
who presented with leukaemia cutis preceding development of acute
myeloid leukaemia. Leukaemic infiltration of the skin should be
considered an early manifestation of leukaemic transformation and an
indicator of poor prognosis in MDS.
19
UI - 11801312
AU - Paz-y-Mino C; Burgos R; Morillo SA; Santos JC; Fiallo BF; Leone PE
TI -
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute
lymphoblastic leukemia in Ecuador, South America.
SO - Cancer Genet Cytogenet 2002 Jan 1;132(1):65-7
AD - Laboratorio de Genetica Molecular y Citogenetica Humana, Departamento de
Ciencias Biologicas, Pontificia Universidad Catolica del Ecuador, P.O.
Box 17-1-2184, Quito, Ecuador. cpazymino@puceuio.puce.edu.ec
Different BCR-ABL transcript variants occur more or less frequently,
according to the leukemia type. We report the frequencies of BCR-ABL
transcript variants studied in chronic myeloid leukemia (CML) and acute
lymphoblastic leukemia (ALL) patients in the Ecuadorian population. The
frequencies found for CML patients in this study were 94.6% for the
b2/a2 rearrangement and 5.4% for the b3/a2 rearrangement; whereas in
ALL, all cases (100%) that presented the BCR-ABL rearrangement had the
e1/a2 junction. Since our results differ from the frequencies previously
reported, we suggest that this may be due to a different genetic
background in the population involved in this study when compared to the
populations analyzed in prior studies. Furthermore, we recommend a
survey of the BCR-ABL transcript variants and their frequencies in
different ethnic groups.
20
UI - 11801317
AU - Qian J; Xue Y; Sun J; Guo Y; Pan J; Wu Y; Wang W; Yao L
TI -
Constitutional Robertsonian translocations in (9;22)-positive chronic
myelogenous leukemia.
SO - Cancer Genet Cytogenet 2002 Jan 1;132(1):79-80
21
UI - 11843399
AU - Jain SP; Henry RJ
TI -
Haematocolpos following allogenic bone marrow transplantation for
chronic myeloid leukaemia.
SO - BJOG 2001 Dec;108(12):1309-10
AD - Department of Obstetrics and Gynaecology, Poole General Hospital, UK.
22
UI - 11826673
AU - Somers JA; Shamelian SO; Lowenberg B; Ossenkoppele GJ; Cornelissen JJ
TI -
[STI571: a new dimension in the treatment of chronic myeloid leukemia]
SO - Ned Tijdschr Geneeskd 2002 Jan 19;146(3):128-32
AD - Erasmus Medisch Centrum-Daniel den Hoed Kliniek, afd. Hematologie,
Groene Hilledijk 301, 3075 EA Rotterdam.
Three patients suffering from chronic myelogenous leukaemia (CML), a
36-year-old woman in blast crisis, and a 64-year-old woman and a
60-year-old man in the chronic phase, participated in a clinical trial
with STI571, a recently developed tyrosine kinase inhibitor with
relative specificity for the BCR-ABL kinase. In all three patients,
complete haematologic remission occurred within 2 months of the
treatment being initiated. Subsequently the patient in blast crisis
underwent allogeneic stem-cell transplantation. For the second patient,
who had experienced many side effects with the standard treatment,
STI571 led to a better quality of life. The third patient reached
complete cytogenetic remission after 3 months of treatment. The
development of STI571 is a major breakthrough in the treatment of CML.
There are few side effects and the short-term results are excellent in
specific patient categories. Further research is needed to establish the
eventual role of STI571 in the treatment of CML.
23
UI - 11853786
AU - Griffin JD
TI -
Resistance to targeted therapy in leukaemia.
SO - Lancet 2002 Feb 9;359(9305):458-9
AD - Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
james_griffin@dfci.harvard.edu
24
UI - 11856174
AU - Gidali J; Laszlo E; Halm G; Feher I
TI -
Blast colony-forming cell binding from CML bone marrow, or blood, on
stromal layers pretreated with G-CSF or SCF.
SO - Cell Prolif 2002 Feb;35(1):1-7
AD - National Institute of Haematology and Immunology, Budapest, Hungary.
j.gidali@ohvi.hu
Blast colony-forming cells (CFU-BL) represent a specific subpopulation
of special primitive progenitors characterized by colony formation only
in close contact with a preformed stromal layer. CFU-BL derived from
bone marrow of chronic myeloid leukaemia (CML) patients have been proved
to adhere poorly to bone marrow derived stromal layers suggesting that
the appearance of progenitors and precursors in the circulation is due
to a defective adhesion of these cells to the bone marrow
microenvironment. In the present experiments the effect of short-term
incubation of preformed normal bone marrow stroma on the adherence of
CML derived CFU-BL was studied. For stroma cultures bone marrow cells
were cultured in microplates in the presence of hydrocortisone. Cultures
were used when stromal layers became confluent and no sign of
haemopoiesis could be observed. CFU-BL were studied by panning plastic
non-adherent mononuclear (PNAMNC) bone marrow or blood cells. 8.9 +/-
2.4 colonies/103 PNAMNC (six experiments) were formed from normal bone
marrow on stromal layers and 4.8 +/- 2.1 colonies/103 PNAMNC (five
experiments) from CML bone marrow. Colony formation from normal bone
marrow was not increased if stromal layers were incubated with 100 ng/mL
granulocyte colony-stimulating factor (G-CSF) or stem cell factor (SCF).
Incubation of stroma with G-CSF or SCF, however, increased the colony
formation of PNAMNC from CML bone marrow or blood significantly. These
findings suggest that local concentration of haemopoietic growth factors
at the time of panning may influence the attachment of CML progenitors
to the stroma.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
